Key Figures Q4 2023
SEK m, unless otherwise stated |
2023 |
2022 |
2023 |
2022 |
% Change |
|
Net revenues | 166.0 | 156.1 | 638.8 | 624.3 | 2.3% | |
Cost of goods sold | -20.1 | -25.9 | -88.9 | -102.6 | -13.4% | |
Operating expenses | -154.5 | -201.3 | -659.5 | -705.6 | -6.5% | |
EBIT | -8.6 | -71.1 | -109.5 | -183.9 | 40.5% | |
EBIT margin, % | -5.2% | -45.6% | -17.1% | -29.5% | 42.0% | |
EBITDA | 12.4 | -53.1 | -32.5 | -115.2 | 71.8% | |
Earnings per share, before dilution, SEK | -0.54 | -2.67 | -3.73 | -5.17 | 27.8% | |
Earnings per share, after dilution, SEK | -0.54 | -2.67 | -3.73 | -5.17 | 27.8% | |
Cash flow from operating activities | -2.6 | -48.9 | -95.0 | -156.6 | 39.3% | |
Cash and invested funds | 171.0 | 351.9 | 171.0 | 351.9 | -51.4% |
Net revenues and EBIT per segment Q4 2023
|
Net Revenues |
EBIT |
||||||
|
2023 |
2022 |
2023 |
2022 |
2023 |
2022 |
2023 |
2022 |
ZUBSOLV® US | 151.3 | 142.6 | 577.7 | 571.4 | - | - | - | - |
US Pharma – total | 151.3 | 142.6 | 577.7 | 571.4 | 75.4 | 77.0 | 283.1 | 308.4 |
Digital Therapeutics (DTx) product sales | 0.0 | 0.0 | 0.0 | 0.4 | - | - | - | - |
Digital Therapeutics (DTx) – total | 0.0 | 0.0 | 0.0 | 0.4 | -29.1 | -49.0 | -130.9 | -189.1 |
Abstral® royalties | 10.0 | 5.5 | 31.9 | 30.4 | - | - | - | - |
Edluar® royalties | 1.9 | 2.7 | 10.8 | 10.4 | - | - | - | - |
ZUBSOLV® - ex US | 2.8 | 5.2 | 18.4 | 11.8 | - | - | - | - |
HQ & Pipeline - total | 14.7 | 13.4 | 61.1 | 52.6 | -54.9 | -99.1 | -261.8 | -303.2 |
Total | 166.0 | 156.1 | 638.8 | 624.3 | -8.6 | -71.1 | -109.5 | -183.9 |
Cash flow Q4 2023
SEK m |
2023 |
2022 |
2023 |
2022 |
|
Cash flow from operating activities | -2.6 | -48.9 | -95.0 | -156.6 | |
Investment activities | -0.9 | 66.2 | 200.8 | -234.7 | |
Financing activities | -5.6 | -5.8 | -70.1 | -21.4 | |
Cash flow (excl exchange rate differences) | -9.1 | 11.5 | 35.7 | -412.8 | |
Cash and cash equivalents | 171.0 | 132.2 | 171.0 | 132.2 |